Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Child Development | 14 | 2023 | 93 | 2.110 |
Why?
|
| HIV Infections | 27 | 2024 | 5097 | 1.550 |
Why?
|
| Adolescent | 33 | 2025 | 2985 | 1.510 |
Why?
|
| Humans | 66 | 2025 | 14537 | 1.370 |
Why?
|
| Growth Disorders | 4 | 2020 | 56 | 1.330 |
Why?
|
| Mental Disorders | 4 | 2016 | 44 | 1.130 |
Why?
|
| Child | 27 | 2024 | 2242 | 1.120 |
Why?
|
| Family Health | 4 | 2014 | 16 | 1.120 |
Why?
|
| Cognition | 6 | 2021 | 75 | 1.100 |
Why?
|
| Parent-Child Relations | 3 | 2014 | 16 | 1.040 |
Why?
|
| Child Welfare | 4 | 2009 | 16 | 1.010 |
Why?
|
| Mental Health | 5 | 2025 | 91 | 1.010 |
Why?
|
| Female | 42 | 2025 | 9103 | 0.980 |
Why?
|
| Child, Preschool | 19 | 2023 | 1748 | 0.960 |
Why?
|
| Child, Orphaned | 5 | 2022 | 16 | 0.960 |
Why?
|
| Poverty | 4 | 2023 | 152 | 0.940 |
Why?
|
| Government | 1 | 2024 | 13 | 0.910 |
Why?
|
| Research Design | 2 | 2024 | 124 | 0.810 |
Why?
|
| Male | 29 | 2025 | 6754 | 0.770 |
Why?
|
| South Africa | 26 | 2025 | 7596 | 0.760 |
Why?
|
| Risk-Taking | 2 | 2019 | 121 | 0.750 |
Why?
|
| Mothers | 5 | 2024 | 195 | 0.750 |
Why?
|
| Hepatitis B, Chronic | 3 | 2011 | 45 | 0.730 |
Why?
|
| Alcohol Drinking | 2 | 2025 | 55 | 0.710 |
Why?
|
| Adolescent, Institutionalized | 1 | 2020 | 1 | 0.700 |
Why?
|
| Child, Institutionalized | 1 | 2020 | 1 | 0.700 |
Why?
|
| Institutionalization | 1 | 2020 | 2 | 0.690 |
Why?
|
| Health Promotion | 5 | 2023 | 109 | 0.680 |
Why?
|
| Caregivers | 3 | 2023 | 76 | 0.680 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 20 | 0.670 |
Why?
|
| Anti-HIV Agents | 8 | 2021 | 1324 | 0.660 |
Why?
|
| Child Health | 1 | 2020 | 77 | 0.660 |
Why?
|
| Hepatitis B virus | 3 | 2011 | 157 | 0.660 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 60 | 0.650 |
Why?
|
| Parenting | 5 | 2024 | 22 | 0.650 |
Why?
|
| Social Support | 3 | 2024 | 77 | 0.650 |
Why?
|
| Quality of Life | 2 | 2022 | 177 | 0.650 |
Why?
|
| Adult | 22 | 2024 | 5913 | 0.590 |
Why?
|
| Ecology | 1 | 2017 | 5 | 0.580 |
Why?
|
| Infant | 12 | 2024 | 2244 | 0.580 |
Why?
|
| Antiviral Agents | 3 | 2010 | 111 | 0.550 |
Why?
|
| Cohort Studies | 8 | 2025 | 967 | 0.540 |
Why?
|
| Schools | 4 | 2025 | 73 | 0.540 |
Why?
|
| Child of Impaired Parents | 3 | 2009 | 9 | 0.480 |
Why?
|
| Nutritional Status | 1 | 2015 | 76 | 0.480 |
Why?
|
| Models, Theoretical | 2 | 2014 | 80 | 0.470 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 411 | 0.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2014 | 187 | 0.460 |
Why?
|
| HLA Antigens | 2 | 2011 | 50 | 0.440 |
Why?
|
| Infant, Newborn | 6 | 2024 | 1479 | 0.420 |
Why?
|
| Breast Feeding | 2 | 2016 | 120 | 0.410 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2011 | 12 | 0.400 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2023 | 472 | 0.390 |
Why?
|
| Intimate Partner Violence | 2 | 2022 | 55 | 0.390 |
Why?
|
| Hepatitis B e Antigens | 1 | 2011 | 26 | 0.380 |
Why?
|
| Child Abuse | 4 | 2022 | 10 | 0.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2022 | 6 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 9 | 0.350 |
Why?
|
| Global Health | 6 | 2020 | 193 | 0.340 |
Why?
|
| Young Adult | 10 | 2024 | 2498 | 0.330 |
Why?
|
| Prevalence | 5 | 2020 | 1192 | 0.320 |
Why?
|
| Depression | 3 | 2025 | 121 | 0.310 |
Why?
|
| Africa | 4 | 2023 | 376 | 0.310 |
Why?
|
| United Nations | 3 | 2023 | 12 | 0.300 |
Why?
|
| Rural Population | 4 | 2024 | 654 | 0.300 |
Why?
|
| Cholagogues and Choleretics | 1 | 2007 | 1 | 0.300 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2007 | 1 | 0.300 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 9 | 0.300 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2023 | 529 | 0.300 |
Why?
|
| Liver Diseases | 1 | 2007 | 18 | 0.300 |
Why?
|
| Family Characteristics | 1 | 2008 | 135 | 0.290 |
Why?
|
| Pregnancy | 9 | 2024 | 1862 | 0.280 |
Why?
|
| Developing Countries | 3 | 2022 | 400 | 0.270 |
Why?
|
| Genetic Variation | 1 | 2008 | 175 | 0.270 |
Why?
|
| Pregnant Women | 2 | 2024 | 89 | 0.270 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 265 | 0.270 |
Why?
|
| Ribavirin | 1 | 2006 | 15 | 0.270 |
Why?
|
| Interferon-alpha | 1 | 2006 | 15 | 0.270 |
Why?
|
| Drug Costs | 1 | 2006 | 18 | 0.260 |
Why?
|
| Hepacivirus | 1 | 2006 | 37 | 0.260 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2006 | 11 | 0.260 |
Why?
|
| Hepatitis C, Chronic | 1 | 2006 | 26 | 0.260 |
Why?
|
| Health Services Accessibility | 7 | 2023 | 280 | 0.260 |
Why?
|
| Cross Infection | 1 | 2006 | 52 | 0.250 |
Why?
|
| Mutation | 3 | 2022 | 306 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 5 | 2021 | 551 | 0.240 |
Why?
|
| Celiac Artery | 1 | 2004 | 1 | 0.240 |
Why?
|
| Ligaments | 1 | 2004 | 1 | 0.240 |
Why?
|
| Abdominal Pain | 1 | 2004 | 7 | 0.240 |
Why?
|
| Running | 1 | 2004 | 6 | 0.240 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 9 | 0.240 |
Why?
|
| Sexual Behavior | 3 | 2022 | 320 | 0.240 |
Why?
|
| Anxiety | 1 | 2025 | 40 | 0.240 |
Why?
|
| Prospective Studies | 4 | 2020 | 1160 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2010 | 472 | 0.230 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 353 | 0.230 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 253 | 0.220 |
Why?
|
| Health Personnel | 1 | 2006 | 231 | 0.220 |
Why?
|
| Social Work | 1 | 2023 | 2 | 0.220 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 239 | 0.210 |
Why?
|
| Policy Making | 1 | 2023 | 32 | 0.210 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.200 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2016 | 196 | 0.200 |
Why?
|
| Urban Population | 1 | 2024 | 257 | 0.200 |
Why?
|
| Problem Behavior | 1 | 2022 | 6 | 0.200 |
Why?
|
| Qualitative Research | 2 | 2024 | 321 | 0.200 |
Why?
|
| Behavior Therapy | 1 | 2021 | 11 | 0.200 |
Why?
|
| Resilience, Psychological | 2 | 2014 | 11 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 7 | 0.190 |
Why?
|
| Health Services | 1 | 2021 | 51 | 0.190 |
Why?
|
| House Calls | 1 | 2021 | 9 | 0.190 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 263 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1422 | 0.190 |
Why?
|
| Crime Victims | 1 | 2020 | 5 | 0.180 |
Why?
|
| Sex Offenses | 1 | 2020 | 29 | 0.180 |
Why?
|
| Far East | 1 | 2020 | 1 | 0.170 |
Why?
|
| Orphanages | 1 | 2020 | 2 | 0.170 |
Why?
|
| Africa, Northern | 1 | 2020 | 5 | 0.170 |
Why?
|
| Asia, Central | 1 | 2020 | 2 | 0.170 |
Why?
|
| Residential Facilities | 1 | 2020 | 3 | 0.170 |
Why?
|
| North America | 1 | 2020 | 11 | 0.170 |
Why?
|
| Latin America | 1 | 2020 | 10 | 0.170 |
Why?
|
| Middle East | 1 | 2020 | 8 | 0.170 |
Why?
|
| Europe | 1 | 2020 | 56 | 0.170 |
Why?
|
| Asia | 1 | 2020 | 72 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 11 | 0.170 |
Why?
|
| Violence | 1 | 2020 | 68 | 0.170 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 139 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 5 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2019 | 9 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 44 | 0.160 |
Why?
|
| Health Status | 1 | 2020 | 111 | 0.160 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 563 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 244 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 11 | 0.140 |
Why?
|
| Age Factors | 2 | 2008 | 370 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2008 | 42 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 25 | 0.140 |
Why?
|
| Executive Function | 1 | 2016 | 23 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 142 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2022 | 799 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 279 | 0.130 |
Why?
|
| Risk Factors | 4 | 2022 | 1475 | 0.120 |
Why?
|
| Middle Aged | 4 | 2019 | 3601 | 0.120 |
Why?
|
| Mass Screening | 1 | 2016 | 245 | 0.120 |
Why?
|
| Child Nutrition Disorders | 1 | 2014 | 13 | 0.120 |
Why?
|
| Internationality | 1 | 2014 | 36 | 0.120 |
Why?
|
| Child Abuse, Sexual | 1 | 2014 | 4 | 0.110 |
Why?
|
| United States | 1 | 2014 | 132 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2014 | 22 | 0.110 |
Why?
|
| Health Services Needs and Demand | 3 | 2010 | 57 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 370 | 0.110 |
Why?
|
| Child Health Services | 1 | 2013 | 35 | 0.110 |
Why?
|
| Health Resources | 1 | 2013 | 66 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2013 | 115 | 0.100 |
Why?
|
| Stress, Psychological | 2 | 2010 | 28 | 0.100 |
Why?
|
| Adaptation, Biological | 1 | 2011 | 5 | 0.100 |
Why?
|
| China | 1 | 2011 | 21 | 0.100 |
Why?
|
| Australia | 1 | 2011 | 48 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 24 | 0.100 |
Why?
|
| Malaria | 1 | 2014 | 213 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 99 | 0.090 |
Why?
|
| Phylogeny | 1 | 2011 | 231 | 0.090 |
Why?
|
| Patient Rights | 1 | 2010 | 3 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2010 | 64 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2021 | 151 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 181 | 0.080 |
Why?
|
| Malawi | 2 | 2023 | 87 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 26 | 0.080 |
Why?
|
| Tanzania | 2 | 2022 | 88 | 0.080 |
Why?
|
| Vulnerable Populations | 1 | 2008 | 30 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 43 | 0.080 |
Why?
|
| Social Perception | 1 | 2008 | 7 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 48 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2014 | 543 | 0.080 |
Why?
|
| Hypertension, Portal | 1 | 2007 | 1 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2007 | 3 | 0.070 |
Why?
|
| Educational Status | 2 | 2021 | 68 | 0.070 |
Why?
|
| Human Rights | 1 | 2008 | 12 | 0.070 |
Why?
|
| World Health Organization | 1 | 2008 | 137 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2008 | 57 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 435 | 0.070 |
Why?
|
| Disease Progression | 1 | 2007 | 154 | 0.070 |
Why?
|
| HIV-1 | 2 | 2021 | 1260 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 253 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 3 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 10 | 0.070 |
Why?
|
| Genotype | 1 | 2008 | 442 | 0.070 |
Why?
|
| Peptides | 1 | 2006 | 40 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 49 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 73 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 112 | 0.060 |
Why?
|
| Quarantine | 1 | 2025 | 5 | 0.060 |
Why?
|
| Syndrome | 1 | 2004 | 19 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2006 | 303 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2007 | 889 | 0.060 |
Why?
|
| Nigeria | 1 | 2024 | 49 | 0.060 |
Why?
|
| Nutritional Support | 1 | 2024 | 5 | 0.060 |
Why?
|
| Zambia | 1 | 2024 | 115 | 0.060 |
Why?
|
| Standard of Care | 1 | 2024 | 30 | 0.060 |
Why?
|
| Depression, Postpartum | 1 | 2024 | 22 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2024 | 85 | 0.060 |
Why?
|
| Altruism | 1 | 2023 | 7 | 0.060 |
Why?
|
| Health Facilities | 1 | 2024 | 40 | 0.060 |
Why?
|
| Focus Groups | 1 | 2024 | 196 | 0.050 |
Why?
|
| Health Policy | 1 | 2024 | 140 | 0.050 |
Why?
|
| Interdisciplinary Studies | 1 | 2023 | 4 | 0.050 |
Why?
|
| Protective Factors | 1 | 2023 | 7 | 0.050 |
Why?
|
| Probability | 1 | 2023 | 27 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 27 | 0.050 |
Why?
|
| Vaccination | 1 | 2024 | 365 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 256 | 0.050 |
Why?
|
| Child Behavior | 1 | 2022 | 11 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2022 | 55 | 0.050 |
Why?
|
| Africa, Southern | 1 | 2021 | 91 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 6 | 0.050 |
Why?
|
| Uganda | 1 | 2021 | 197 | 0.050 |
Why?
|
| Mozambique | 1 | 2021 | 55 | 0.050 |
Why?
|
| Biomarkers | 1 | 2022 | 327 | 0.050 |
Why?
|
| Aged | 1 | 2006 | 1740 | 0.050 |
Why?
|
| Language Development | 1 | 2020 | 4 | 0.040 |
Why?
|
| Condoms | 1 | 2021 | 88 | 0.040 |
Why?
|
| Body Height | 1 | 2020 | 52 | 0.040 |
Why?
|
| Adalimumab | 1 | 2019 | 1 | 0.040 |
Why?
|
| Infliximab | 1 | 2019 | 2 | 0.040 |
Why?
|
| Victoria | 1 | 2019 | 2 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 10 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 175 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 80 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 819 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 1 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 4 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2017 | 14 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 20 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2017 | 45 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 41 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 50 | 0.030 |
Why?
|
| Apoptosis | 1 | 2017 | 40 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 30 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 96 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 62 | 0.030 |
Why?
|
| Mice | 1 | 2017 | 135 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 199 | 0.030 |
Why?
|
| Students | 1 | 2016 | 50 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 127 | 0.030 |
Why?
|
| Social Environment | 1 | 2014 | 11 | 0.030 |
Why?
|
| Health Surveys | 1 | 2014 | 59 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 89 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 1081 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 51 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 50 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 32 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 133 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2014 | 120 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 120 | 0.030 |
Why?
|
| Capacity Building | 1 | 2013 | 32 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 43 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 262 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 656 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hunger | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2010 | 48 | 0.020 |
Why?
|
| Family Relations | 1 | 2010 | 7 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2010 | 16 | 0.020 |
Why?
|
| Malnutrition | 1 | 2010 | 56 | 0.020 |
Why?
|
| Financial Support | 1 | 2009 | 10 | 0.020 |
Why?
|
| Income | 1 | 2009 | 85 | 0.020 |
Why?
|